Press Release

Our enduring purpose: to fundamentally improve the lives of patients with serious diseases in ways never before possible.

Five Prime Therapeutics to Participate in the 2020 Wedbush PacGrow Healthcare Virtual Conference

July 29, 2020 at 7:00 PM EDT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 29, 2020-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that Tom Civik, Chief Executive Officer of Five Prime Therapeutics, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer of Five Prime Therapeutics, will participate in a fireside chat at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 10:10am Pacific Time (PT) / 1:10pm Eastern Time (ET)

The fireside chat will be webcast and may be accessed from the “Events & Presentations” section of the Company’s website at: http://investor.fiveprime.com/events.cfm. Five Prime will maintain an archived replay of the webcast on its website for approximately 30 days after the conference.

About Five Prime

Five Prime Therapeutics, Inc. develops innovative protein therapeutics to improve the lives of patients with cancer. Five Prime’s product candidates have innovative mechanisms of action and address patient populations in need of better cancer therapies. The company focuses on developing immuno-oncology and targeted cancer therapies paired with companion diagnostics to identify patients who are most likely to benefit from treatment with Five Prime’s product candidates. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit https://www.fiveprime.com.

Source: Five Prime Therapeutics, Inc.

Media and Investor Contact
Martin Forrest
VP, Investor Relations & Corporate Communications
Five Prime Therapeutics, Inc.
415-365-5625
martin.forrest@fiveprime.com

Source: Five Prime Therapeutics, Inc.